The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Mon, Tuesday and today
After two director buys.
Bingo.!!
Not all trades are shown on ADVFN Search google for ISDX Then tap in AKT
" There is a palpable sense that British investors are re-discovering a taste for biotech stocks, which have not been in favour for years. Last week's float of Circassia, which is developing treatments to prevent allergic reaction to cats and pollen, is a sure sign these stocks are coming back into vogue"
TODAYS SUNDAY TIMES; DOPE FIENDS ENJOY $1BN LAST LAUGH; "As just as virtually every retailer under the sun seems eager to capitalise on the city's float mania, it seems likely that a fair few biotechs will look at the success of GW PHARMA, CIRCASSIA and others and take the plunge, too." AKT has rather a lot going for it,[in my view;] MARKET CAP £1.1M AKT is fully listed on the LSE not AIM. It is a Biotech with a massive tax loss of £120M It is a cash shell. [Cash at 14/7/13 was £1.1M with another £400,000 net of cash due by 31/12/13.] The directors have stated the plan is to do a deal [RTO] or hand the cash back to shareholders within the first half of this year. The right place at the right time comes to mind.!
With all your views. Buy when you can at half price and the risk goes towards zero. Plus any deal should be great fun.
2nd strong day of buying.
Do an RTO / deal or hand the cash pile back in the first half. If all cash has been collected since 30/06/13 then after running costs your looking at £1.350,000
£35,000 worth yesterday. With a £5.60 broker valuation one can understand why. New CEO with a great track record in the sector.
Just under two weeks left for the share price to hit 12P or their options are worthless.
Up again today
Ark has lost £150M since its float on the LSE; [10 years ago] However its still listed.!! My money is on ARK to produce rather more for shareholders from its very low base today, than Circassia that came to the market this week. The name of the game is to buy low and sell high The city ******s tend to get it the wrong way round. Just love how they dump ARK for a 99.57% loss.!!! CORRECTED-UPDATE 1-Allergy drug firm Circassia prices London listing at top of range Thu, 13th Mar 2014 08:53 By Freya Berry LONDON, March 13 (Reuters) - British allergy treatment firm Circassia priced its initial public share offer at the top of its price range on Thursday, in the biggest biotech debut on the London market for years. The listing at 310 pence per share values the company at about 581 million pounds ($965 million), making it the largest biotech IPO since at least 1995, according to life science publication EP Vantage. The last major IPO in the sector was Ark Therapeutics which raised 55 million pounds ($91.3 million) in London in 2004.
A very long way to go yet
Built up 6% of a fully listed company: Been down under for 7 weeks
Cash just short of double today's share price. Options an extra 4m shares run out on 31/03/14 Those options only any good to the directors if used above 12p by the above date (double today's share price) So two ways this goes both are very good for shareholders 1/ The share price through some kind of deal / news goes above 12p within days. 2/ the options fail on 31/03/14 and the companies real value goes up as not burdened by any options. Note also the Gums are held for free within the company.!!
Westhouse the house broker has lifted the stock to a buy. 03-Mar-14 Westhouse Securities Buy 560.00 560.00 Upgrade 14-Oct-13 Westhouse Securities Add 475.00 500.00 Downgrade 30-Aug-13 Westhouse Securities Buy 360.00 475.00 Reiteration 25-Jul-13 Westhouse Securities Buy 360.00 360.00 Reiteration 21-May-13 WH Ireland Buy 0.00 320.00 New Coverage 08-Apr-13 Westhouse Securities Buy 360.00 360.00 Reiteration
PTO, CBUY AND MAC ARE MY 2014 RESEARCHED STOCKS. HAPPY NEW YEAR. HEMSCOTT STOCK CHALLENGE 2013. TARAS STOCKS WIN HANDS DOWN. Position details: Tue, 31 Dec 2013 12:15:00 Position Name Profit Spread Loss Stock Selections Best 1 1 evenley 166.59% 166.00 TCG 286.95% AGL 78.00 178.57% WSG 75.00 163.16% IDG 60.00 118.18% PTO 335.00 86.11%
Publishing Technology has issued a trading update In today’s trading update Publishing Technology (PT) has outlined that it expects results for the year to December 2013 to be below market expectations, due to a combination of delays in completing a number of large projects and accelerated R&D investment. As a result, profits for FY2013 are expected to be similar to FY2012. As management’s expectations for FY2014 remain unchanged we are revising our FY2013 estimates for adj. PBT and adj. EPS to £0.6m from £1.3m previously) and 7.6p (from 14.9p previously). We leave our FY2014 forecasts for adj. PBT and adj. EPS of £1.8m and 21.4p unchanged. Today’s update signals that China is performing well, with the JV on track to deliver an operating profit in this financial year, and it is benefitting from a growing pipeline of opportunities. Management have also taken the opportunity today to confirm that it has not received an approach for, or held discussions regarding a takeover of, the company. While today’s trading update may disappoint some, accelerated R&D should aid market adoption of advance, and does not negatively impact the fundamental attractions of PT. Our target price of 560p remains based on our FY2014 forecasts, and these are unchanged. We would view any share price weakness as an opportunity to add to holdings.
£0.6M to £1.8M That will = profit growth of a massive 200% [2014 over 2013.!!!] More than happy with that.!!